Skip to main content
MJFF Feed

FDA January Approvals Bring New Parkinson's Therapies to U.S. Market

FDA January Approvals Bring New Parkinson's Therapies to U.S. Market

This past month the U.S. Food and Drug Administration (FDA) approved two new formulations of traditional Parkinson’s therapy levodopa/carbidopa. Both therapies are designed to avoid “off” time in Parkinson’s — when symptoms return before another dose of medication is due.

MJFF-awardee Impax Pharmaceuticals announced the approval of RYTARY, an extended-release, oral capsule formulation of the drug. Phase III clinical trial participants experienced nearly an hour and a half less “off” time per day when taking the drug.

Less than a week later, the FDA approved AbbVie’s Duopa gel formulation of levodopa/carbidopa. The treatment, approved in Europe under the name Duodopa since 2004, is delivered directly into the small intestine via a small infusion pump and tube. The drug bypasses the stomach and thereby some of the absorption issues impacting oral medicine. Duopa requires patients wear a large external “box” in the belt region that may require maintenance.

Listen to a podcast to learn more about “off” episodes. 

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.